Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Expanded Clinical Study of the Tendyne Mitral Valve System

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02321514
Recruitment Status : Active, not recruiting
First Posted : December 22, 2014
Last Update Posted : July 7, 2020
Sponsor:
Information provided by (Responsible Party):
Abbott Medical Devices

Brief Summary:
The purpose of this study is to generate initial insights into the safety and performance of the Tendyne Mitral Valve System. The study includes adult patients with symptomatic mitral regurgitation who are not suitable candidates for conventional mitral valve repair or replacement. The study will include up to 350 subjects at up to 40 centers. Follow-up evaluations will be conducted through 5 years post implantation.

Condition or disease Intervention/treatment Phase
Mitral Valve Regurgitation Device: Tendyne Mitral Valve System Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 350 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Expanded Clinical Study of the Tendyne Mitral Valve System
Actual Study Start Date : November 2014
Actual Primary Completion Date : July 2020
Estimated Study Completion Date : December 2025

Arm Intervention/treatment
Experimental: Tendyne Mitral Valve System
Transcatheter mitral valve replacement
Device: Tendyne Mitral Valve System
Transcatheter mitral valve replacement




Primary Outcome Measures :
  1. Safety assessed by freedom from device or procedure related adverse events [ Time Frame: 30-days ]
  2. Performance assessed by freedom from device malfunction [ Time Frame: 30-days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Severe mitral regurgitation of primary or secondary etiology
  2. NYHA functional Class ≥ II. If IV, patient must be ambulatory
  3. Heart team determines patient is not a suitable candidate for traditional surgical treatment
  4. Age 18 years or older

Exclusion Criteria:

  1. Severe mitral calcification or mitral stenosis
  2. Chest condition that prevents transapical access
  3. Prior surgical or interventional treatment of mitral or aortic valves

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02321514


Locations
Show Show 38 study locations
Sponsors and Collaborators
Abbott Medical Devices
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Abbott Medical Devices
ClinicalTrials.gov Identifier: NCT02321514    
Other Study ID Numbers: CS-03
First Posted: December 22, 2014    Key Record Dates
Last Update Posted: July 7, 2020
Last Verified: July 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Mitral Valve Insufficiency
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases